- Home
- AKRO
as 02-21-2025 4:00pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2019 |
| Target Price: | $75.86 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.86 - $58.40 | Next Earning Date: | 03-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rolph Timothy | AKRO | Chief Scientific Officer | Feb 5 '25 | Sell | $56.62 | 18,750 | $1,059,629.65 | 176,140 | |
| Young Jonathan | AKRO | Chief Operating Officer | Feb 3 '25 | Sell | $53.81 | 10,000 | $538,060.80 | 251,147 | |
| Yale Catriona | AKRO | Chief Development Officer | Jan 27 '25 | Sell | $56.04 | 49,074 | $2,734,212.41 | 104,348 | |
| Cheng Andrew | AKRO | President and CEO | Jan 27 '25 | Sell | $55.66 | 30,000 | $1,646,977.98 | 721,820 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Jan 27 '25 | Sell | $55.78 | 31,250 | $1,742,958.33 | 176,140 | |
| Young Jonathan | AKRO | Chief Operating Officer | Jan 2 '25 | Sell | $28.03 | 10,000 | $280,330.00 | 251,147 | |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | Dec 31 '24 | Sell | $57.03 | 5,000 | $285,150.00 | 33,492 | |
| Yale Catriona | AKRO | Chief Development Officer | Dec 16 '24 | Sell | $29.11 | 9,074 | $264,116.92 | 104,348 | |
| Rolph Timothy | AKRO | Chief Scientific Officer | Dec 16 '24 | Sell | $31.10 | 3,800 | $118,172.40 | 176,140 | |
| Lamy Patrick | AKRO | Senior VP, Commercial Strategy | Dec 16 '24 | Sell | $29.13 | 1,000 | $29,130.00 | 33,492 |
Latest Akero Therapeutics Inc. News
AKRO Breaking Stock News: Dive into AKRO Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025
MT Newswires
10 days ago
Akero Therapeutics Insider Sold Shares Worth $1,581,994, According to a Recent SEC Filing
MT Newswires
12 days ago
Akero Therapeutics Insider Bought Shares Worth $9,600,000, According to a Recent SEC Filing
MT Newswires
17 days ago
Akero Therapeutics Insider Sold Shares Worth $538,061, According to a Recent SEC Filing
Insider Monkey
19 days ago
Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025
Insider Monkey
19 days ago
Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High
Motley Fool
20 days ago
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Insider Monkey
20 days ago
Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?
Compare AKRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKRO Akero Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.